AI Generated
Jul 2, 2026, 10:29
Nisar Ahmed: The Evolution of Anticoagulation Therapy
Nisar Ahmed, Pharmacist at Zubair Pharmacy, shared a post on LinkedIn:
“70 years of warfarin vs the new generation.
Here’s why anticoagulation has changed forever.
Warfarin — blocks vitamin K clotting factors, needs constant INR monitoring, dozens of food and drug interactions.
Still irreplaceable for mechanical heart valves.
Apixaban (Eliquis) — directly inhibits Factor Xa, predictable, no monitoring, fewer interactions.
The landmark ARISTOTLE trial: 21% less stroke, 31% less major bleeding, 11% lower mortality vs warfarin in AF.
- Mechanical heart valve? Stick with warfarin – DOACs are contraindicated.
- Non-valvular AF or VTE? Apixaban is now the standard of care.
- Full breakdown in the infographic . “
Stay updated with Hemostasis Today.
-
Aug 9, 2026, 12:26Mohamed Rawy: When Is a Reduced DOAC Dose Appropriate?
-
Aug 9, 2026, 11:22Saqib Ullah: Why Do Red Blood Cells Autoagglutinate
-
Aug 9, 2026, 11:06Oumayma Mnafe: ThroLy and IMPEDE VTE Scores in Hematologic Malignancies
-
Aug 9, 2026, 10:06Care Shouldn’t Depend on Where You Live – National Bleeding Disorders Foundation
-
Aug 9, 2026, 10:01Irma Bagdoniene: Plaque Stability and the Importance of LDL Lowering
-
Aug 9, 2026, 09:49Rana Al-Dhalaan: New Study Examines Viral Infections in Blood Donors
-
Aug 9, 2026, 09:29Michael Wilkinson: How Lp(a) Shapes Coronary Plaque and Cardiovascular Risk
-
Aug 9, 2026, 09:16Preparing for Gene Therapy Starts with Understanding Immunity – WFH
-
Aug 9, 2026, 08:46Christina Pohlman: Uncovering the Autoantibodies Behind APS